Hyponatremia Associated with Valproate Therapy
Introduction to Hyponatremia Risk
- The American Academy of Neurology recommends baseline and periodic monitoring of serum sodium levels in patients on valproate therapy, especially during initiation of therapy, after dose increases, in elderly patients, in patients with low body weight, and in patients on multiple medications 1
Management and Treatment
- Correction of sodium should not exceed 8 mmol/L per day to avoid central pontine myelinolysis, according to the European Society of Neurology 1
- If severe (sodium <130 mmol/L) or symptomatic, consider discontinuation of valproate and switching to an alternative antiepileptic with lower risk (such as lamotrigine or gabapentin) 1
Clinical Monitoring
- Clinical monitoring for signs and symptoms of hyponatremia is recommended, including early signs such as headache, nausea, vomiting, lethargy, and advanced signs such as confusion, somnolence, seizures, coma 1